WOODBRIDGE, ON, April 7, 2015 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health and the University Hospital of Strasbourg, are pleased to announce today that POMEGA trial chief investigator Dr. Yannick Georg has been designated laureate of the EUR 30,000 young researcher French Interregional Clinical Research and Innovation (GIRCI Est) Award.
Source: www.newswire.ca
The post Pivotal Therapeutics and French University Announce Chief Investigator Dr. Yannick Receives GIRCI Award appeared first on Invest in York - Toronto Area's Tech Hub.